Personalized Retinal Disease Treatment Platform
Legal Citation
Summary of the Inventive Concept
A wearable ocular device with a MEMS-based delivery mechanism and integrated sensor for real-time retinal health monitoring, enabling personalized treatment of retinal diseases through a cloud-based data analytics module.
Background and Problem Solved
The original patent disclosed compositions and methods for the inhibition of diabetic retinopathy and retinal vein occlusion using cell permeant therapeutics. However, these methods rely on manual administration of eye drops, which can be inconvenient and may lead to inconsistent treatment outcomes. The new inventive concept addresses these limitations by introducing a wearable ocular device that provides controlled and sustained delivery of therapeutics, while also monitoring retinal health in real-time.
Detailed Description of the Inventive Concept
The wearable ocular device comprises a reservoir containing a cell permeant therapeutic, a MEMS-based delivery mechanism, and a sensor that monitors the patient's retinal health. The device can be programmed to deliver the therapeutic at predetermined intervals based on the patient's retinal health data, which is transmitted to a cloud-based data analytics module. The module provides personalized treatment recommendations to the patient, ensuring optimal treatment outcomes. The system enables real-time monitoring and adaptation to changing retinal health conditions, thereby improving treatment efficacy and patient quality of life.
Novelty and Inventive Step
The new claims introduce a paradigm shift in retinal disease treatment by integrating wearable technology, MEMS-based delivery, and cloud-based data analytics. The inventive concept's novelty lies in its ability to provide personalized, real-time treatment adaptation, which is not possible with manual eye drop administration.
Alternative Embodiments and Variations
Alternative embodiments may include varying the type of sensor used, incorporating additional features such as artificial intelligence-powered predictive analytics, or using different materials for the wearable ocular device. Variations may also include adapting the system for treatment of other ocular diseases or integrating with existing medical devices.
Potential Commercial Applications and Market
The personalized retinal disease treatment platform has significant commercial potential in the ophthalmology and healthcare industries, with potential applications in diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration treatment. The market for such a platform is substantial, with an estimated global value of over $10 billion by 2025.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/55 |
| A | A61 | A61K9/0048 |
| A | A61 | A61K47/64 |
| A | A61 | A61P27/02 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering and ophthalmological drug delivery systems, focusing on targeted therapeutic interventions for retinal diseases with expertise in micro-scale delivery mechanisms, cell-penetrating peptides, and personalized medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with advanced degrees, experience in ocular drug delivery, microfluidic systems, and familiarity with emerging medical device technologies and personalized treatment platforms
Obviousness Rationale
A PHOSITA would recognize that the wearable ocular device with integrated sensor and controlled drug delivery represents a predictable technological progression from the source patent's cell-penetrating therapeutic approach, leveraging known micro-electromechanical systems (MEMS) and digital health monitoring technologies to enhance targeted drug administration for retinal diseases. The integration of real-time monitoring and adaptive delivery mechanisms would be considered an obvious extension of existing therapeutic strategies, particularly given the growing trend toward personalized medical technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,609 |
|---|---|
| Title | Ocular delivery of cell permeant therapeutics for the treatment of retinal edema |
| Assignee(s) | The Trustees of Columbia University in the City of New York |